CureVac’s Flop Shows Pfizer, Moderna Made mRNA Look Too Easy (2)

June 18, 2021, 12:02 PM

The rapid development and remarkable efficacy of Covid-19 shots from Pfizer Inc. and Moderna Inc. created sky-high expectations for the novel technology they employ. CureVac NV’s vaccine disappointment shows that not every messenger-RNA project will live up to hopes.

The German biotech firm made some crucial choices that set its candidate apart. Although the trial results it published earlier this week aren’t directly comparable, and the proliferation of viral variants has complicated studies since the other shots were tested last year, experts say key differences between the vaccines probably played a major role in CureVac’s weak results.

One key ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.